Suzhou University and MaoXing Bio Establish First Cell Therapy Collaborative Innovation Center

Nov 06, 2023 07:19 CST Updated 07:20

Maximum Biology

Developer of Novel Immunotherapy Technologies

November 4th,"Action Plan for the Enhancement of Collaborative Innovation in Suzhou's Biomedical Industry" --- Cell Therapy Field Seminar Successfully Held.According to the construction requirements of China's National Innovation-Driven Demonstration Cities by the China Association for Science and Technology,Initiated by the Suzhou Science and Technology Association, facilitated by the government, the first event was led by Suzhou Maoxing Biotechnology Co., Ltd., supported by universities and research institutes, and participated in by relevant academic organizations.Integrate the elements of government, industry, academia, research, service, finance, and application in Suzhou's biopharmaceuticals sector, and take the lead in implementing actions to enhance collaborative innovation in Suzhou's biopharmaceuticals industry.

Attendees of the conference included Ni Zhiqiang, Vice Chairman of Suzhou Association for Science and Technology; Jiang Jingdong, Secretary of the Party Committee of Science and Technology at Soochow University; Lu Xiaochun from Suzhou Science and Technology Bureau; Zhong Zhiyuan, Dean of the School of Pharmaceutical Science at Soochow University; Zhang Hao, Director of the Collaborative Innovation Management Office of the Academy of Science Research at Soochow University; Zheng Yiran from the School of Pharmaceutical Science at Soochow University; Huang Yulun, Director of the Neurosurgery Department at Dushu Lake Hospital of Soochow University; as well as representatives from companies such as Suzhou Maoxing Biotechnology Co., Ltd., New Landscape Bio, Findem Therapeutics, and Prajñā Bio. Invited guests included Academician Sun Lingyun, President of the Second Affiliated Hospital of Anhui Medical University; Dr. Tang Yiwei, Chief Medical Officer of Danaher China Diagnostic Platform; Li Huabing from Shanghai Institute of Immunology; and Zhao Tingting, Executive Dean of Chongqing International Institute of Immunology. The meeting was chaired by Shang Xiaoyun, CEO of Suzhou Maoxing Biotechnology Co., Ltd.

The meeting fully utilized the role of enterprises as problem posers, established and improved the five-party topic selection and project initiation mechanism, and accelerated the exploration of the collaborative innovation "Suzhou Model" focusing on "academic forums + project platforms + talented elites," helping to build Suzhou's biopharmaceutical industry as the top high-quality development model in China and globally.

Dean Zhong ZhiyuanOpening Remarks for This Conference: Recognition and gratitude were expressed to Suzhou Maoxing Biotechnology Co., Ltd. for organizing the first event of the "Suzhou Biomedical Industry Collaborative Innovation Enhancement Action Plan" with a focus on cell therapy. The supportive policies of Soochow University towards the biomedical industry in Suzhou were introduced. Soochow University highly values its integrated development with the city of Suzhou. President Zhang Xiaohong of Soochow University proposed three major strategies: the “Famous City, Prestigious University” strategy, the talent strategy, and the international cooperation strategy, which are closely aligned with this collaborative innovation action plan. Prestigious universities promote famous cities, advancing the alignment between academic disciplines and industries, jointly attracting and cultivating high-end talents in the biomedical industry, leveraging the leading role of enterprises in talent attraction, utilizing specialized channels of institutions for talent recruitment, establishing shared talent recruitment, mutual hiring, and cooperative talent cultivation mechanisms, actively promoting the "affiliation with academic institutions, work in enterprises" talent collaboration mechanism, increasing efforts in industrializing research achievements, integrating the governmental, industrial, academic, research, service, financial, and application elements of Suzhou’s biomedical industry, and fully promoting the implementation of the collaborative innovation enhancement action plan.

Jiang Jingdong, Secretary of the Science and Technology Party Committee of Soochow University, stated:"The unique aspect of Jiangsu Province's collaborative innovation model lies in its enterprise-centric market approach, involving the联动of enterprises, research institutes, universities, and the government. It firmly adheres to the integration of production and demand, emphasizes talent recruitment and cultivation, and jointly advances the transformation of innovative scientific achievements, ultimately achieving the goal of using technological innovation to serve the public."

Representative of the participating company: MaoxingBiological Little CloudDr. Peng Songming from Xinjing Zhhiyuan, Dr. Li Jun from Fangdemen Da, and Dr. Hu Minjie from Banruo Bio introduced the basic situation of their companies and raised issues and needs encountered during the development process.

The experts and leaders present introduced their respective organizations' and fields' opinions and suggestions on the development of Suzhou's biopharmaceutical industry, particularly in the cell therapy sector, and provided constructive answers to the questions raised by the enterprises.

At the conference site, Nanjing Drum Tower Hospital and Suzhou Maoxing Biotechnology Co., Ltd. signed a strategic cooperation agreement. Based on integrating their respective professional advantages, the two parties will carry out strategic cooperation on "Universal CAR-T Cell Therapy for Autoimmune Diseases" to achieve integrated alignment in cell drug research and development, clinical studies, and clinical transformation.

Jiang Jingdong, Secretary of the Science and Technology Party Committee of Soochow University, Ni Zhiqiang, Vice Chairman of the Suzhou Association for Science and Technology, Zhong Zhiyuan, Dean of the School of Pharmaceutical Science of Soochow University, and Zhao Tingting, Executive Dean of Chongqing International Immunology Research Institute, unveiled the "Soochow University-Suzhou Maoxing Biotechnology Co., Ltd. Cell Drug Collaborative Innovation Center" and the "Chongqing International Immunology Research Institute Cell Industry Transformation Base" in the presence of all attendees.

The meeting concluded with active and in-depth open discussions among the participating leaders, experts, research institutes, and enterprises.

After listening to the active and in-depth open discussions from the participants,Vice Chairman of Suzhou Science and Technology Association, Mr. Ni ZhiqiangIn the final summary speech, the event was fully affirmed for its efficient and pragmatic approach as a pilot initiative. It was emphasized that the enhancement action of Suzhou's biomedicine industry collaboration is an effective measure to implement the innovation-driven development strategy and to carry out the important speech spirit of President Xi Jinping during his inspection of Jiangsu, particularly Suzhou. The action strengthens the principal role of enterprises, upholds the concept that serving enterprises equates to promoting productivity, advances the integration of industrial innovation clusters, and promotes the convergence of innovative elements toward enterprises. It aims to build bridges to deepen the consensus on collaboration; rely on research institutes to solidify breakthroughs in innovation challenges; and focus on enterprises to better align with developmental goals. It adheres to the seven aspects of government, industry, academia, research, finance, application, and service, concentrating on the two key areas of industry and academia. It explores the construction of a tool-based information platform, integrates academic systems through colleges and academic organizations, focuses on enterprise services at the industry end, and improves the mechanism of the scientist-entrepreneur collaborative innovation alliance, striving to promote the deep integration of technology and economy for high-quality development.

About Suzhou Maoxing Biotechnology Co., Ltd.

Suzhou Maoxing Biotechnology Co., Ltd. is dedicated to the development of universal cell drugs, utilizing the ultimate form of cell therapy to explore treatments for diseases that currently have no effective medications. The team is composed of renowned experts in immunotherapy and gene editing, as well as seasoned professionals from the biopharmaceutical industry. The company's core technology platform, a gene-edited allogeneic immune cell therapy, employs a fully proprietary version 3.0 solution to achieve universal allogeneic CAR-T cell treatment. This addresses the risks of graft-versus-host disease and rejection associated with allogeneic immune cells. The resulting allogeneic CAR-T cells can persist in patients' bodies for extended periods, delivering optimal therapeutic effects, placing the technology at an internationally leading level. The company is currently focused on advanced malignant tumors, with its first product pipeline for recurrent glioma showing breakthrough efficacy and controllable safety in preliminary clinical studies. The company plans to bring at least one product to market within the next five years and advance multiple products into Phase II clinical trials.

Suzhou Maoxing Biotechnology Co., Ltd. always adheres to the corporate philosophy of "upholding integrity, innovating quietly, and synergistic integration," insisting on addressing clinical issues with no available treatments as its core value. It strives to overcome challenges in its specialized field, focusing on true original innovation, aiming to become a globally leading innovative company in cell therapy, providing solutions for diseases that are "beyond medical help."